Online citations, reference lists, and bibliographies.
← Back to Search

Tumor-targeted PE38KDEL Delivery Via PEGylated Anti-HER2 Immunoliposomes.

Jie Gao, W. Zhong, Jinqiu He, Huimei Li, H. Zhang, Guichen Zhou, Bohua Li, Y. Lu, H. Zou, Geng Kou, D. Zhang, H. Wang, Y. Guo, Yanqiang Zhong
Published 2009 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
We previously reported the development of PE38KDEL-loaded anti-HER2 poly(lactic-co-glycolic acid) (PLGA) nanoparticles that bind and internalize in HER2-overexpressing breast cancer cells, enabling potent anti-tumor activity. To overcome the problems associated with the short half-lives of this drug delivery system, we have constructed PE38KDEL-loaded anti-HER2 PEGylated liposomes (PE-HER-liposomes). PE-HER-liposomes were constructed with Fab' of recombinant humanized anti-HER2 monoclonal antibody (anti-HER2 Fab') covalently linked to PEGylated liposomes containing PE38KDEL (PE-liposomes). We attached anti-HER2 Fab' to the terminus of PEG (polyethylene glycol) on PEGylated liposomes. Incorporation of pyridylthiopropionoylamino-PEG-distearoylphosphatidylethanolamine (PDP-PEG-DSPE) into PEGylated liposomes followed by mild thiolysis of the PDP groups resulted in the formation of reactive thiol groups at the periphery of the liposomes. Efficient attachment of maleimide-derivatized anti-HER2 Fab' took place under mild conditions. The characterization of PE-HER-liposomes, such as particle size, was evaluated by dynamic light-scattering detector. The Micro BCA method was used to determine the encapsulation efficiency of PE38KDEL and the quantity of conjugated Fab'. Flow cytometry and confocal microscopy showed that PE-HER-liposomes possessed receptor-specific binding and internalization for HER2-overexpressing SK-BR3 cells. Remarkably, PE-HER-liposomes were more cytotoxic than non-targeted PE-liposomes in HER2-overexpressing breast cancer cells. In conclusion, PE-HER-liposomes could serve as a promising therapeutic candidate for the treatment of HER2-overexpressing breast cancers.
This paper references
10.1016/S0163-7827(03)00033-X
Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties.
S. Moghimi (2003)
10.1016/S0168-3659(98)00050-9
A new preparation method for protein loaded poly(D, L-lactic-co-glycolic acid) microspheres and protein release mechanism study.
T. Park (1998)
10.1016/J.CANLET.2004.03.038
Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia.
A. Ito (2004)
10.1016/S0163-7827(03)00032-8
Ligand-targeted liposomal anticancer drugs.
P. Sapra (2003)
10.1016/J.JCONREL.2007.03.012
Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody.
P. Kocbek (2007)
10.1146/ANNUREV.MED.58.070605.115320
Immunotoxin treatment of cancer.
I. Pastan (2007)
10.1016/J.IJPHARM.2004.10.009
In vitro and in vivo evaluation of actively targetable nanoparticles for paclitaxel delivery.
Zhenghong Xu (2005)
10.1038/nrc1891
Immunotoxin therapy of cancer
I. Pastan (2006)
10.1016/0005-2736(95)00085-H
A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells.
T. Allen (1995)
10.1016/S0005-2736(01)00411-4
Targeting Stealth liposomes in a murine model of human small cell lung cancer.
J. Moreira (2001)
10.1053/J.SEMINONCOL.2004.08.009
Future directions of liposome- and immunoliposome-based cancer therapeutics.
J. Park (2004)
10.1007/s10549-008-0043-0
PE38KDEL-loaded anti-HER2 nanoparticles inhibit breast tumor progression with reduced toxicity and immunogenicity
Jie Gao (2008)
10.1177/39.12.1940325
Application of the FITC-anti-FITC-gold system to ultrastructural localization of antigens.
G. V. van Dam (1991)
In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
D. E. Lopes de Menezes (1998)
10.1016/J.IJPHARM.2005.09.012
Distribution of liposomal breviscapine in brain following intravenous injection in rats.
Wenli Lv (2005)
10.1016/J.IJPHARM.2005.09.016
In vivo study of liposomes as drug carriers to oral mucosa using EPR oximetry.
V. Erjavec (2006)
10.1016/j.jconrel.2008.03.010
Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy.
H. Chen (2008)
10.1016/J.IJPHARM.2007.02.011
Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation.
T. Yang (2007)
10.1016/J.PEP.2005.04.004
Preparation and characterization of fusion protein truncated Pseudomonas Exotoxin A (PE38KDEL) in Escherichia coli.
Shuichuan Song (2005)
10.1126/SCIENCE.1095833
Drug Delivery Systems: Entering the Mainstream
T. Allen (2004)
10.1073/pnas.221450098
Brain-specific expression of an exogenous gene after i.v. administration
N. Shi (2001)
10.1021/BI00517A043
Immunospecific targeting of liposomes to cells: a novel and efficient method for covalent attachment of Fab' fragments via disulfide bonds.
F. Martín (1981)
10.1007/s00280-005-0076-6
Pharmacokinetic and cytotoxic studies of pegylated liposomal daunorubicin
H. Song (2005)



This paper is referenced by
10.3109/02652048.2011.552989
Preparation and in vitro evaluation of anti-VCAM-1-Fab′-conjugated liposomes for the targeted delivery of the poorly water-soluble drug celecoxib
D. Kang (2011)
10.1007/978-1-4939-3634-2_7
Targeting Cancer Using Nanocarriers
Dalit Landesman-Milo (2016)
10.1016/J.BEJ.2018.08.003
Effects of arginine-based surface modifications of liposomes for drug delivery in Caco-2 colon carcinoma cells
K. Neuberger (2018)
10.1016/j.ijpharm.2012.04.054
Investigation on the stability of saquinavir loaded liposomes: implication on stealth, release characteristics and cytotoxicity.
L. N. Ramana (2012)
10.1080/08982104.2018.1430829
Effective suppression of tumour cells by oligoclonal HER2-targeted delivery of liposomal doxorubicin
A. Farasat (2019)
10.1016/j.ejpb.2015.03.018
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Edgar Pérez-Herrero (2015)
10.2217/nnm.13.118
Current trends in the use of liposomes for tumor targeting.
Pranali P. Deshpande (2013)
10.1517/17425241003596337
Microemulsions as drug delivery systems to improve the solubility and the bioavailability of poorly water-soluble drugs
Cai-Xia He (2010)
10.1007/978-3-319-16555-4_11
Engineering the nanoparticle-protein interface for cancer therapeutics.
A. Saie (2015)
10.2217/nnm-2019-0459
HER-2/neu and MYC gene silencing in breast cancer: therapeutic potential and advancement in nonviral nanocarrier systems.
Jananee Padayachee (2020)
10.3389/fbioe.2020.575365
Targeting Fluorescence Imaging of RGD-Modified Indocyanine Green Micelles on Gastric Cancer
J. Shao (2020)
10.31274/ETD-180810-4642
The effect of macrophage phenotype and surface modification of liposomes on internalization
Lilusi Ma (2016)
10.2217/nnm-2020-0010
Lignin-graft-PLGA drug-delivery system improves efficacy of MEK1/2 inhibitor in triple-negative breast cancer cell line.
C. Byrne (2020)
10.2174/092986712800784720
Drug targeting to cancer by nanoparticles surface functionalized with special biomolecules.
M. A. Holgado (2012)
10.1016/j.ejps.2012.02.007
Hepatocellular carcinoma targeting effect of PEGylated liposomes modified with lactoferrin.
Minyan Wei (2012)
10.1002/jps.23640
Preparation and characterization of insulin-surfactant complexes for loading into lipid-based drug delivery systems.
P. Li (2013)
10.1081/E-EBPP-120049265
Ligand-Appended Liposomes: Targeted Breast Cancer Therapy
S. Paliwal (2015)
10.3109/10731199.2010.494578
Advances in Novel Drug Delivery Strategies for Breast Cancer Therapy
Ritu Dhankhar (2010)
10.1155/2012/212965
The Treatment of Breast Cancer Using Liposome Technology
S. Brown (2012)
10.1177/0885328215578111
Functional liposomes in the cancer-targeted drug delivery
D. Tila (2015)
10.30827/ars.v51i3.4855
Revisión del estado actual y posibilidades de las aproximaciones más importantes al transporte específico de agentes quimioterápicos a las células tumorales.
E. Sáez-Fernández (2010)
Receptor Targeting Liposomal Nano Formulations for Drug Delivery in Breast Cancer
Vyas (2019)
10.1016/j.colsurfb.2017.07.085
Immunoliposomes: A review on functionalization strategies and targets for drug delivery.
Josimar O. Eloy (2017)
10.1039/c5nr06305a
Stimuli-free programmable drug release for combination chemo-therapy.
L. Fan (2016)
10.2174/138920012798356899
The ligand nanoparticle conjugation approach for targeted cancer therapy.
Nour Karra (2012)
10.1007/978-1-4614-5456-4_18
Design, Development, and Characterization of Recombinant Immunotoxins Targeting HER2/neu
Yu Cao (2013)
Advanced Drug Delivery Systems - a Synthetic and Biological Applied Evaluation
Lise Nørkjær Bjerg (2013)
10.1038/nrd4333
Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery
V. Torchilin (2014)
10.1016/j.biomaterials.2019.119646
Surface engineering of nanomaterials with phospholipid-polyethylene glycol-derived functional conjugates for molecular imaging and targeted therapy.
Dinglin Zhang (2019)
10.1039/B923535N
Liposomes as ‘smart’ pharmaceutical nanocarriers
R. Sawant (2010)
A novel antineoplastic nano-lipobubble drug delivery system for passively targeted ovarian cancer therapy
Derusha Frank (2015)
Chemoenzymatic surface modification of liposomal drug carriers
Steffen Wöll (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar